OHR Pharmaceutical, Inc operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-682-8452
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees3
Next Earnings Date1/1/2020 (Estimated)
OptionableOptionable
OHR Pharmaceutical (NASDAQ:OHRP) Frequently Asked Questions
What is OHR Pharmaceutical's stock symbol?
OHR Pharmaceutical trades on the NASDAQ under the ticker symbol "OHRP."
When did OHR Pharmaceutical's stock split? How did OHR Pharmaceutical's stock split work?
Shares of OHR Pharmaceutical reverse split on the morning of Monday, February 4th 2019. The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 1st 2019. An investor that had 100 shares of OHR Pharmaceutical stock prior to the reverse split would have 5 shares after the split.
How were OHR Pharmaceutical's earnings last quarter?
When is OHR Pharmaceutical's next earnings date?
Has OHR Pharmaceutical been receiving favorable news coverage?
Media stories about OHRP stock have trended somewhat negative recently, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OHR Pharmaceutical earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for OHR Pharmaceutical.
Who are some of OHR Pharmaceutical's key competitors?
Some companies that are related to OHR Pharmaceutical include Aridis Pharmaceuticals (ARDS), Pharmaxis (PXSLY), Oramed Pharmaceuticals (ORMP), Agile Therapeutics (AGRX), Alpine Immune Sciences (ALPN), Arbutus Biopharma (ABUS), SUMMIT THERAPEU/S (SMMT), Spring Bank Pharmaceuticals (SBPH), Iterum Therapeutics (ITRM), ASLAN PHARMACEU/ADR (ASLN), Moleculin Biotech (MBRX), OTCMKTS:EMBI (EMBI), Eyenovia (EYEN), Vascular Biogenics (VBLT) and CTI BioPharma (CTIC).
What other stocks do shareholders of OHR Pharmaceutical own?
Who are OHR Pharmaceutical's key executives?
OHR Pharmaceutical's management team includes the folowing people:
- Dr. Jason Scott Slakter, CEO, Pres & Director (Age 61)
- Mr. Samuel Backenroth, CFO, VP of Bus. Devel. & Sec. (Age 35)
- Dr. Glenn L. Stoller M.D., Chief Scientific Officer (Age 55)
- Dr. Marlene Modi, Head of Preclinical & Regulatory Affairs
How do I buy shares of OHR Pharmaceutical?
Shares of OHRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
How big of a company is OHR Pharmaceutical?
What is OHR Pharmaceutical's official website?
How can I contact OHR Pharmaceutical?
OHR Pharmaceutical's mailing address is 800 THIRD AVENUE 11TH FLOOR, NEW YORK NY, 10022. The biotechnology company can be reached via phone at 212-682-8452 or via email at [email protected]
MarketBeat Community Rating for OHR Pharmaceutical (NASDAQ OHRP)
MarketBeat's community ratings are surveys of what our community members think about OHR Pharmaceutical and other stocks. Vote "Outperform" if you believe OHRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OHRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
